Brief: Sensei Biotherapeutics To Present New Data For SNS-101 At The Society For Immunotherapy Of Cancer
01/10/2021 13:24
Oct 1 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS TO PRESENT NEW PRECLINICAL DATA FOR
SNS-101, A PROPRIETARY ANTI-VISTA ANTIBODY, AT THE 36TH ANNUAL
MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)
Source text for Eikon: ID:nGNX6fktb9
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)